ストックスクリーナーアプリを入手
2.79
1.09%
0.03
アフターアワーズ：
2.79
前日終値:
$2.76
開ける：
$2.75
24時間の取引高:
1.38M
Relative Volume:
0.94
時価総額：
$296.61M
収益：
$58.36M
当期純損益:
$-25.72M
株価収益率:
-7.6627
EPS:
-0.3641
ネットキャッシュフロー:
$-24.91M
1週間 パフォーマンス:
-7.00%
1か月 パフォーマンス:
+8.14%
6か月 パフォーマンス:
-48.90%
1年 パフォーマンス:
-15.20%
1日の値動き範囲:
$2.68
$2.805
1週間の範囲:
$2.59
$3.005
52週間の値動き範囲:
$2.20
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
名前
Aquestive Therapeutics Inc
セクター
電話
908-941-1900
住所
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
2.79 | 296.61M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 開始されました | Leerink Partners | Outperform |
| 2024-04-11 | 開始されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2019-04-22 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-03 | 開始されました | Lake Street | Buy |
| 2018-08-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-08-20 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Aquestive Therapeutics Inc (AQST) 最新ニュース
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Barclays PLC - Defense World
Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday - Defense World
Aquestive Therapeutics (AQST) Q1 Earnings Preview: Expectations and Revisions - GuruFocus
Aquestive Therapeutics Inc (AQST) Q1 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Raymond James Financial Inc. Acquires New Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by Wells Fargo & Company MN - Defense World
Aquestive Therapeutics at Citizens JMP: Strategic Moves in Allergy Treatment - Investing.com Australia
Quarterly Metrics: Quick and Current Ratios for Aquestive Therapeutics Inc (AQST) - DWinneX
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference - The Manila Times
Aquestive Therapeutics CEO Fireside Chat: Key Updates Coming at Citizens Life Sciences Conference - Stock Titan
Renaissance Technologies LLC Boosts Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Invesco Ltd. Reduces Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential - Seeking Alpha
JPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Inc (AQST) deserves deeper analysis - uspostnews.com
Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET - The Manila Times
Aquestive Therapeutics to Report First Quarter 2025 - GlobeNewswire
Aquestive Therapeutics Inc (AQST) receives an Overweight rating from Cantor Fitzgerald - knoxdaily.com
Aquestive Therapeutics Inc’s Market Journey: Closing Weak at 2.83, Down -1.39 - DWinneX
Anaphylaxis Treatment Market Size in 7MM is expected to grow at - openPR.com
The 14% return this week takes Aquestive Therapeutics' (NASDAQ:AQST) shareholders three-year gains to 105% - simplywall.st
Geode Capital Management LLC Trims Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Russell Investments Group Ltd. Has $386,000 Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Check out these key findings about Aquestive Therapeutics Inc (AQST) - Sete News
Is Aquestive Therapeutics Inc (AQST) worth investing in despite its overvalued state? - uspostnews.com
Recent Insider Activity Suggests Potential Gains for Aquestive Therapeutics Inc (AQST) - knoxdaily.com
Investor’s Delight: Aquestive Therapeutics Inc (AQST) Closes Strong at 2.58, Up 2.79 - DWinneX
Does Aquestive Therapeutics Inc (NASDAQ: AQST) Still Need To Convince Analysts? - Stocksregister
Vanguard Group Inc. Grows Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Vanguard Group Inc. Raises Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - The AM Reporter
Wellington Management Group LLP Has $639,000 Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength? - Yahoo Finance
Raymond James Financial Inc. Makes New Investment in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive completes marketing application for Anaphylm in U.S. - MSN
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - The Manila Times
Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium - GlobeNewswire Inc.
Raymond James Financial Inc. Invests $498,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World
HC Wainwright Reaffirms “Buy” Rating for Aquestive Therapeutics (NASDAQ:AQST) - Defense World
New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by HighTower Advisors LLC - Defense World
Aquestive’s Anaphylm shows promise in pediatric study By Investing.com - Investing.com South Africa
Aquestive’s Anaphylm shows promise in pediatric study - Investing.com India
Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks
Aquestive Therapeutics Inc (AQST) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
1.62%
大文字化:
|
ボリューム (24 時間):